Where’s the data? In a pandemic, now is no time to sit on Covid-19 trial results
When Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, described the results of a remdesivir study a couple of weeks ago, he was cautious in characterizing how the experimental Gilead Sciences drug helped combat Covid-19.
Patients given the intravenous medicine recovered faster than those on a placebo by 31%, or four days, Fauci said, conceding the result was not a “knockout.” Nonetheless, he insisted in his trademark keep-it-simple-demeanor, that the data showed “remdesivir has a clear-cut, significant, positive effect…. This has proven that a drug can block this virus.”
